News

RTS Life Science plans to launch its Tube Auditor instrument. The Tube Auditor features vision technology (patent pending), which allows fast and accurate volume measurement of samples, and

BiondVax has completes the Phase I/II clinical trial of the Multimeric-001 Universal Flu vaccine. The trials were conducted at the Sourasky Medical Center in Tel Aviv, Israel. The

Van Andel Institute (VAI) has expanded its 240,000 square foot facility with an investment of $178m on December 8, 2009. The expanded facility creates economic and scientific opportunity

McKesson is set to introduce the PROmanager-Rx system, a solution that enables hospitals to fully automate the dispensing of tablets, capsules, and other oral solid medications that come pre-packaged from

Facet Biotech (Facet) and Bristol-Myers Squibb have reported positive data from a phase I/II study of Elotuzumab, an investigational humanised antibody being studied for the treatment of relapsed

Nutra Pharma has submitted the final packaging and labeling to the FDA to begin selling Nyloxin OTC, an over-the-counter treatment for moderate-to-severe (Stage 2) chronic pain, and Nyloxin

Æterna Zentaris has reported Phase 3 results for its European efficacy trial Z-036 in benign prostatic hyperplasia (BPH), with Cetrorelix Pamoate. Study Z-036 did not reach its primary

The Dow Chemical has formed a new independent company known as Pfenex through its Dow Venture Capital group. The new company, headquartered in San Diego, California, is based

Genzyme has presented data from its CAM314 randomised Phase 3 clinical trial comparing Campath (alemtuzumab) in combination with Fludara (fludarabine phosphate) (FluCAM) to Fludara alone in patients with